4.5 Article

Comparison of influenza vaccine effectiveness using different methods of case detection: Clinician-ordered rapid antigen tests vs. active surveillance and testing with real-time reverse-transcriptase polymerase chain reaction (rRT-PCR)

Journal

VACCINE
Volume 29, Issue 3, Pages 387-390

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.10.082

Keywords

Influenza vaccine effectiveness; Rapid test; Polymerase chain reaction

Funding

  1. Centers for Disease Control and Prevention [1 UO1 CI000192-02, U18IP000183]

Ask authors/readers for more resources

Annual evaluation of influenza vaccine effectiveness (VE) is needed to assess ongoing impact of immunization efforts in the setting of antigenic drift and periodic vaccine reformulation. Optimal methodology for determining VE remains unclear. We compared influenza VE generated from prospective enrollment and rRT-PCR testing (active surveillance group) with VE based on clinician-ordered diagnostic tests (clinical testing group) in a defined population over four seasons. VE was calculated as (1 - adjusted OR) for vaccination in cases vs. test-negative controls. VE based on clinical testing underestimated VE based on active surveillance and testing with rRT-PCR by 5-33% depending on season. (C) 2010 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Immunology

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Testing and Detection During Peripartum Hospitalizations Among a Multicenter Cohort of Pregnant Persons: March 2020-February 2021

Miranda J. Delahoy, Flor Munoz, De-Kun Li, Carmen Sofia Arriola, Nanette Lee Bond, Michael Daugherty, Jeannette Ferber, Nickolas Ferguson, Louise Hadden, Jillian T. Henderson, Stephanie A. Irving, Mary Juergens, Venkatesh Kancharla, Mara Greenberg, Roxana Odouli, Gabriella Newes-Adeyi, Erin G. Nicholson, Lawrence Reichle, Momodou Sanyang, Margaret Snead, Fatimah S. Dawood, Allison L. Naleway

Summary: This study analyzed electronic health record data from pregnant individuals at three healthcare networks in the US to investigate SARS-CoV-2 testing practices during peripartum hospitalizations. The findings revealed potential disparities in testing based on demographic and pregnancy characteristics, highlighting the need for equitable testing practices and care for pregnant individuals with SARS-CoV-2 infections.

CLINICAL INFECTIOUS DISEASES (2023)

Editorial Material Infectious Diseases

COVID-19 vaccination protects children and adolescents

Stephanie A. Irving, Nicola P. Klein

LANCET INFECTIOUS DISEASES (2023)

Article Immunology

Protection of Two and Three mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized With COVID-19-VISION Network, August 2021 to March 2022

Malini B. DeSilva, Patrick K. Mitchell, Nicola P. Klein, Brian E. Dixon, Mark W. Tenforde, Mark G. Thompson, Allison L. Naleway, Shaun J. Grannis, Toan C. Ong, Karthik Natarajan, Sarah E. Reese, Ousseny Zerbo, Anupam B. Kharbanda, Palak Patel, Edward Stenehjem, Chandni Raiyani, Stephanie A. Irving, William F. Fadel, Suchitra Rao, Jungmi Han, Sue Reynolds, Jonathan M. Davis, Ned Lewis, Charlene McEvoy, Monica Dickerson, Kristin Dascomb, Nimish R. Valvi, Michelle A. Barron, Kristin Goddard, Gabriela Vazquez-Benitez, Nancy Grisel, Mufaddal Mamawala, Peter J. Embi, Bruce Fireman, Inih J. Essien, Eric P. Griggs, Julie Arndorfer, Manjusha Gaglani

Summary: This study assessed the impact of COVID-19 vaccination on illness severity among hospitalized adults with COVID-19. The findings showed that vaccination with 2 or 3 mRNA vaccine doses was associated with reduced ICU admission and in-hospital death, as well as shorter hospital stays.

JOURNAL OF INFECTIOUS DISEASES (2023)

Article Immunology

Vaccine Effectiveness Against Influenza-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2021-2022 Season, VISION Network

Mark W. Tenforde, Zachary A. Weber, Malini B. DeSilva, Edward Stenehjem, Duck-Hye Yang, Bruce Fireman, Manjusha Gaglani, Noah Kojima, Stephanie A. Irving, Suchitra Rao, Shaun J. Grannis, Allison L. Naleway, Lindsey Kirshner, Anupam B. Kharbanda, Kristin Dascomb, Ned Lewis, Alexandra F. Dalton, Sarah W. Ball, Karthik Natarajan, Toan C. Ong, Emily Hartmann, Peter J. Embi, Charlene E. McEvoy, Nancy Grisel, Ousseny Zerbo, Margaret M. Dunne, Julie Arndorfer, Kristin Goddard, Monica Dickerson, Palak Patel, Julius Timbol, Eric P. Griggs, John Hansen, Mark G. Thompson, Brendan Flannery, Nicola P. Klein

Summary: During the 2021-2022 United States influenza season with predominant influenza A(H3N2) virus circulation, vaccine effectiveness against influenza-associated emergency department/urgent care encounters and hospitalizations were both 25%, with effectiveness varying by age group and presence of immunocompromising conditions.

JOURNAL OF INFECTIOUS DISEASES (2023)

Editorial Material Infectious Diseases

Considerations of hybrid immunity and the future of adolescent COVID-19 vaccination

Stephanie A. Irving, Sarah A. Buchan

LANCET INFECTIOUS DISEASES (2023)

Article Immunology

Incidence Rates of Medically Attended COVID-19 in Infants Less Than 6 Months of Age

Isabel Griffin, Stephanie A. Irving, Carmen Sofia Arriola, Angela P. Campbell, De-Kun Li, Fatimah S. Dawood, Caroline Doughty-Skierski, Jeannette R. Ferber, Nickolas Ferguson, Louise Hadden, Jillian T. Henderson, Mary Juergens, Venkatesh Kancharla, Allison L. Naleway, Gabriella Newes-Adeyi, Erin Nicholson, Roxana Odouli, Lawrence Reichle, Mo Sanyang, Kate Woodworth, Flor M. Munoz

Summary: This study examined the incidence and risk factors of COVID-19 among infants under 6 months of age. The results showed that 1.0% of infants whose mothers received prenatal care had medically attended COVID-19 episodes. Infants born to women with postpartum COVID-19 had a higher risk, highlighting the importance of COVID-19 prevention measures for the household members and caregivers of infants.

PEDIATRIC INFECTIOUS DISEASE JOURNAL (2023)

Article Pediatrics

Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents

Nicola P. Klein, Maria Demarco, Katherine E. Fleming-Dutra, Melissa S. Stockwell, Anupam B. Kharbanda, Manjusha Gaglani, Suchitra Rao, Ned Lewis, Stephanie A. Irving, Emily Hartmann, Karthik Natarajan, Alexandra F. Dalton, Ousseny Zerbo, Malini B. DeSilva, Deepika Konatham, Edward Stenehjem, Elizabeth A. K. Rowley, Toan C. Ong, Shaun J. Grannis, Chantel Sloan-Aagard, Jungmi Han, Jennifer R. Verani, Chandni Raiyani, Kristin Dascomb, Sarah E. Reese, Michelle A. Barron, William F. Fadel, Allison L. Naleway, Juan Nanez, Monica Dickerson, Kristin Goddard, Kempapura Murthy, Nancy Grisel, Zacharay A. Weber, Brian E. Dixon, Palak Patel, Bruce Fireman, Julie Arndorfer, Nimish R. Valvi, Eric P. Griggs, Carly Hallowell, Peter J. Embi, Sarah W. Ball, Mark G. Thompson, Mark W. Tenforde, Ruth Link-Gelles

Summary: This study assessed the effectiveness of the BNT162b2 vaccine against mild to moderate and severe COVID-19 in children and adolescents during the Omicron BA.4/BA.5 period. The results showed that the vaccine had high effectiveness during the Delta period, but the effectiveness decreased during the Omicron period. A monovalent booster increased the effectiveness. Vaccination was recommended for children and adolescents.

PEDIATRICS (2023)

Article Immunology

Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink

Tat'Yana A. Kenigsberg, Kayla E. Hanson, Nicola P. Klein, Ousseny Zerbo, Kristin Goddard, Stanley Xu, W. Katherine Yih, Stephanie A. Irving, Laura P. Hurley, Jason M. Glanz, Robyn Kaiser, Lisa A. Jackson, Eric S. Weintraub

Summary: This study investigated the safety of simultaneous vaccination (SV) with COVID-19 vaccines and other vaccines. The results showed that there were no significant differences in health outcomes between COVID-19 vaccine recipients who received SV and those who did not. Some individual outcomes had statistically significant rate ratios, but the number of outcomes was small and there was no adjustment for multiple testing.

VACCINE (2023)

Article Immunology

Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021

Peter J. Embi, Matthew E. Levy, Palak Patel, Malini B. Desilva, Manjusha Gaglani, Kristin Dascomb, Margaret M. Dunne, Nicola P. Klein, Toan C. Ong, Shaun J. Grannis, Karthik Natarajan, Duck-Hye Yang, Edward Stenehjem, Ousseny Zerbo, Charlene Mcevoy, Suchitra Rao, Mark G. Thompson, Deepika Konatham, Stephanie A. Irving, Brian E. Dixon, Jungmi Han, Kristin E. Schrader, Nancy Grisel, Ned Lewis, Anupam B. Kharbanda, Michelle A. Barron, Sue Reynolds, I-Chia Liao, William F. Fadel, Elizabeth A. Rowley, Julie Arndorfer, Kristin Goddard, Kempapura Murthy, Nimish R. Valvi, Zachary A. Weber, Bruce Fireman, Sarah E. Reese, Sarah W. Ball, Allison L. Naleway

Summary: Immunocompromised (IC) adults have a higher risk of severe COVID-19 outcomes and are less protected by 1-2 vaccine doses compared to non-IC adults. The study found that the vaccine effectiveness against medically attended COVID-19 was lower in IC adults, especially among transplant recipients.

VACCINE (2023)

Article Immunology

Patient and Epidemiological Factors Associated With Influenza Testing in Hospitalized Adults With Acute Respiratory Illnesses, 2016-2017 to 2019-2020

Alexandra F. Dalton, Alexia Couture, Malini B. DeSilva, Stephanie A. Irving, Shruti Gohil, Suchitra Rao, Rebecca Fink, Allison L. Naleway, Zijing Guo, Devi Sundaresan, Rebecca J. Birch, Sarah Ball, Kai Zheng, Toan C. Ong, Carrie Reed, Catherine H. Bozio

Summary: Limited data on influenza testing among adults with acute respiratory illness (ARI)-associated hospitalizations were examined. The study identified important factors associated with influenza testing, such as ARI diagnoses, indicators of influenza activity, and hospital admission month.

OPEN FORUM INFECTIOUS DISEASES (2023)

Article Surgery

Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions-VISION Network, September 2022-April 2023

Ruth Link-Gelles, Zachary A. Weber, Sarah E. Reese, Amanda B. Payne, Manjusha Gaglani, Katherine Adams, Anupam B. Kharbanda, Karthik Natarajan, Malini B. DeSilva, Kristin Dascomb, Stephanie A. Irving, Nicola P. Klein, Shaun J. Grannis, Toan C. Ong, Peter J. Embi, Margaret M. Dunne, Monica Dickerson, Charlene McEvoy, Julie Arndorfer, Allison L. Naleway, Kristin Goddard, Brian E. Dixon, Eric P. Griggs, John Hansen, Nimish Valvi, Morgan Najdowski, Julius Timbol, Colin Rogerson, Bruce Fireman, William F. Fadel, Palak Patel, Caitlin S. Ray, Ryan Wiegand, Sarah Ball, Mark W. Tenforde

AMERICAN JOURNAL OF TRANSPLANTATION (2023)

Article Obstetrics & Gynecology

Influenza Vaccination Among Pregnant People Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic

Stephanie A. Irving, Bradley Crane, Eric Weintraub, Tia L. Kauffman, Neon Brooks, Suchita A. Patel, Hilda Razzaghi, Edward A. Belongia, Matthew F. Daley, Darios Getahun, Sungching C. Glenn, Simon J. Hambidge, Lisa A. Jackson, Elyse Kharbanda, Nicola P. Klein, Ousseny Zerbo, Allison L. Naleway

Summary: Limited data on influenza vaccination coverage among pregnant people in the United States during the COVID-19 pandemic show an increase in annual coverage from the 2016-2017 season to the 2019-2020 season, followed by a decrease in coverage during the COVID-19 pandemic. Coverage was lowest among pregnant people aged 18-24 years and non-Hispanic Black pregnant people. The recent decreases emphasize the need for ongoing efforts to improve vaccination coverage among pregnant people.

OBSTETRICS AND GYNECOLOGY (2023)

Article Immunology

Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines

Tat 'Yana A. Kenigsberg, Kristin Goddard, Kayla E. Hanson, Ned Lewis, Nicola Klein, Stephanie A. Irving, Allison L. Naleway, Bradley Crane, Tia L. Kauffman, Stanley Xu, Matthew F. Daley, Laura P. Hurley, Robyn Kaiser, Lisa A. Jackson, Amelia Jazwa, Eric S. Weintraub

Summary: The US FDA authorized the use of mRNA COVID-19 bivalent booster vaccines, and CDC's clinical guidance allows for simultaneous administration of COVID-19 and other vaccines. A study found that 32.1% of individuals who received a COVID-19 bivalent booster vaccine also received a simultaneous influenza vaccine, which may impact the delivery of immunization services.

VACCINE (2023)

Article Immunology

Influenza vaccination coverage among persons ages six months and older in the Vaccine Safety Datalink in the 2017-18 through 2022-23 influenza seasons

Stephanie A. Irving, Holly C. Groom, Edward A. Belongia, Bradley Crane, Matthew F. Daley, Kristin Goddard, Lisa A. Jackson, Tia L. Kauffman, Tat'Yana A. Kenigsberg, Leslie Kuckler, Allison L. Naleway, Suchita A. Patel, Hung Fu Tseng, Josh T. B. Williams, Eric S. Weintraub

Summary: In the United States, influenza vaccination coverage increased from 2017-18 to 2019-20, then decreased to the lowest level in the 2022-23 season. The lowest coverage was observed among males, individuals aged 18-49, non-Hispanic Black people, and those without high-risk conditions.

VACCINE (2023)

Article Public, Environmental & Occupational Health

Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months-5 Years-VISION Network, United States, July 2022-June 2023

Ruth Link-Gelles, Allison Avrich Ciesla, Elizabeth A. K. Rowley, Nicola P. Klein, Allison L. Naleway, Amanda B. Payne, Anupam Kharbanda, Karthik Natarajan, Malini B. DeSilva, Kristin Dascomb, Stephanie A. Irving, Ousseny Zerbo, Sarah E. Reese, Ryan E. Wiegand, Morgan Najdowski, Toan C. Ong, Suchitra Rao, Melissa S. Stockwell, Ashley Stephens, Kristin Goddard, Yessica C. Martinez, Zachary A. Weber, Bruce Fireman, John Hansen, Julius Timbol, Shaun J. Grannis, Michelle A. Barron, Peter J. Embi, Sarah W. Ball, Manjusha Gaglani, Nancy Grisel, Julie Arndorfer, Mark W. Tenforde, Katherine E. Fleming-Dutra

Summary: On June 19, 2022, the original monovalent mRNA COVID-19 vaccines were approved for children aged 6 months-4 years (Pfizer-BioNTech) and 6 months-5 years (Moderna). On December 9, 2022, CDC expanded recommendations for the use of updated bivalent vaccines to children aged 6 months and above. Effectiveness of the vaccines ranged from 29% to 80% against COVID-19-like illness in children aged 6 months-5 years, depending on the vaccine type and number of doses given. It is important for all children to stay up to date with recommended COVID-19 vaccines.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2023)

No Data Available